Depression, Epinephrine, and Platelet Function

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2002-02-28

Study Completion Date

2009-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Men and women who have suffered sexual and/or physical abuse before the age of 12 are at increased risk for anxiety and mood disorders, other serious psychiatric disorders, and likely medical illnesses. What is not known is whether adult survivors of childhood adversity experience heightened negative emotions and increased physical responses due to altered norepinephrine or serotonin systems in their brains and bodies. The investigators expect to see that survivors of childhood adversity experience heightened negative emotions and increased physical responses to stress.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

An Investigation of the Antidepressant Efficacy of the 5-HT2A Antagonist, M100907, in Combination With Citalopram in Treatment Resistant Depression

NCT00070694

Depressive Disorder

COMPLETED PHASE2

Mechanism of Antidepressant-Related Dysfunctional Arousal in High-Risk Youth

NCT02553161

Depression Anxiety Bipolar Disorder

COMPLETED NA

Study of Brain Response to Emotional Pictures Using a Magnetic Resonance Imaging (fMRI) While on Escitalopram

NCT00707863

Major Depression

COMPLETED PHASE4

Serotonin Transporter Genetic Variation and Amygdala Responses to Antidepressant Medications in Major Depression

NCT02132286

Major Depressive Disorder

COMPLETED PHASE4

Desipramine for Improving Cellular Signaling and Decreasing Symptoms of Major Depression

NCT00320632

Depression

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Major Depressive Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Escitalopram

Group Type ACTIVE_COMPARATOR

Escitalopram

Intervention Type DRUG

10 mg of Escitalopram, and titrated up to 20 mg of Escitalopram after day 22 of intervention

Desipramine

Group Type ACTIVE_COMPARATOR

Desipramine

Intervention Type DRUG

25 mg of Desipramine for day 1-3, 50 mg of Desipramine for day 4-7, 75 mg of Desipramine for day 8-14, 100 mg of Desipramine for day 15-21. Titrated between 125 mg to 200 mg of Desipramine for day 22-56 of intervention

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Escitalopram

10 mg of Escitalopram, and titrated up to 20 mg of Escitalopram after day 22 of intervention

Intervention Type DRUG

Desipramine

25 mg of Desipramine for day 1-3, 50 mg of Desipramine for day 4-7, 75 mg of Desipramine for day 8-14, 100 mg of Desipramine for day 15-21. Titrated between 125 mg to 200 mg of Desipramine for day 22-56 of intervention

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Lexapro Norpramin

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

\-

Exclusion Criteria

* Individuals who are suicidal, psychotic, or with bipolar depression
* alcohol or substance abuse or
* regularly use medications which alter mood or blood vessel function (zolpidem or zalpelon, aspirin, nonsteroidal antiinflammatory drugs, sympatholytics, theophylline, central acting agonists, beta-blockers, coumadin, nitrates, triazolobenzodiazapines, or use steroids (testosterone-patch or pill form), use tryptophan or monoamine oxidase inhibitors (MAOIs),
* have narrow-angle glaucoma, liver disease,
* severe allergies (especially to antidepressants similar to escitalopram or desipramine)
* seizures, or a serious medical disorder (e.g. hypothyroidism) that is unstable or is untreated.
* Depressed patients with a prior history of severe adverse events associated with SSRIs or TCAs will not be accepted into the study.

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes